FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF	CHANGES	IN BENEFI	CIAL	OWNERSH	ΙP
SIAILMENI	OI.	CHANGES	IIA DEIAELI	CIAL	CVVIVEICSIII	

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Chen Daniel ShinYu  (Last) (First) (Middle)  C/O IGM BIOSCIENCES, INC.  325 E. MIDDLEFIELD ROAD						2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [ IGMS ]      3. Date of Earliest Transaction (Month/Day/Year) 05/03/2021								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  Chief Medical Officer					
(Street) MOUNT VIEW	C.		94043 (7in)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individue) X	,				n
(City)	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Table I - Non-Deriv  1. Title of Security (Instr. 3)  2. Trans: Date (Month/L				action	ction 2A. Deemed Execution Date,		3. 4. Securir Transaction Disposed Code (Instr. 5)		rities Acquired (A) of (D) (Instr. 3, 4		or 5. Amou Securitie Benefici Owned I		nt of es ally Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	1	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 0				05/03	/2021				M <sup>(1)</sup>		950	950 A		39	117	117,468		D	
Common Stock 05/03/				3/2021	/2021		F		481(2	2) D	\$68	.03	3 116,987			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion		3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		f g Security nd 4)				Owne Form Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amoun or Number of Shares						
Stock Option (right to buy)	\$1.39	05/03/2021			M <sup>(1)</sup>			950	(3)	1	2/30/2028	Common Stock	950	\$	60.00	343,04	0	D	

## **Explanation of Responses:**

- 1. The option exercise was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- 2. Represents shares withheld by the Issuer to pay the exercise price and taxes pursuant to the "net exercise" of 950 option shares.
- 3. The option, originally for 361,090 shares, of which 18,050 shares have been exercised, vested as to 1/4 of the shares on August 1, 2019, and an additional 1/48 of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person remaining a service provider through each such date.

## Remarks:

/s/ Misbah Tahir, by power of <u>attorney</u>

05/05/2021

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.